Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,700

Sector

Biotechnology & Medical Research

Calendar

Aug. 28 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-10	39.40 $	-0.14%	273,981
25-07-09	39.46 $	+5.24%	1,295,206
25-07-08	37.49 $	+4.52%	1,893,395
25-07-07	35.87 $	+0.65%	1,488,904
25-07-03	35.64 $	-0.75%	604,100

Delayed Quote Nasdaq, July 09, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.46USD

Average target price

75.07USD

Spread / Average Target

+90.26%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:55:49 2025-07-10 am EDT			5-day change	1st Jan Change
39.21 ^USD	-0.62%		+10.19%	+20.68%

Jul. 03	UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	MT
Jun. 30	Legend Biotech Provides Update on REMS for Currently Approves BCMA- and CD19-Directed Autologous Chimeric Antigen Receptor T Cell Immunotherapies	CI

Capitalization	7.27B 6.21B 5.79B 5.35B 9.96B 623B 11.14B 69.28B 26.36B 291B 27.27B 26.71B 1,065B	P/E ratio 2025 *	-42.6x	P/E ratio 2026 *	83.4x
Enterprise value	6.75B 5.76B 5.37B 4.97B 9.25B 578B 10.34B 64.29B 24.46B 270B 25.31B 24.78B 989B	EV / Sales 2025 *	6.6x	EV / Sales 2026 *	4.16x
Free-Float	98.8%	Yield 2025 *	-	Yield 2026 *	-

UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	Jul. 03	MT
Legend Biotech Provides Update on REMS for Currently Approves BCMA- and CD19-Directed Autologous Chimeric Antigen Receptor T Cell Immunotherapies	Jun. 30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	Jun. 30	RE
Legend Biotech Valuation Presents 'Buying Opportunity,' RBC Analysts Say	Jun. 26	MT
SPIC Yuanda Environmental Protection Names Chief Accountant	Jun. 16	MT
Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	Jun. 05	CI
Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study	Jun. 04	MT
Legend Biotech Reports 5-Year Survival Data for Carvykti in Multiple Myeloma	Jun. 03	MT
Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting	Jun. 03	CI
Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting	May. 23	CI
Legend Biotech Corporation Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT	May. 22	CI
Legend Biotech Corporation, Q1 2025 Earnings Call, May 13, 2025	May. 21
Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says	May. 16	MT

RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	Jul. 07	MT
UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	Jul. 03	MT
Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	May. 14	MT
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	Jan. 07	MT
UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	Dec. 09	MT

Legend Biotech Corporation Stock

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Valuation: Legend Biotech Corporation

Chart: Legend Biotech Corporation

Latest news: Legend Biotech Corporation

Last Transcript: Legend Biotech Corporation

Analysts' recommendations: Legend Biotech Corporation

Press Releases: Legend Biotech Corporation

News in other languages: Legend Biotech Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Legend Biotech Corporation

ETFs: Legend Biotech Corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI in Multiple Myeloma at 2025 ASCO Annual Meeting	Jun. 04	AQ
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting	Jun. 03	GL
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT	May. 22	GL
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	May. 19	GL
Legend Biotech : LEGN Q1 2025 Slides 5.9.25	May. 13	PU

J&J dépasse les attentes au 1er trimestre et ajuste ses prévisions annuelles	Apr. 15
En Direct des Marchés : Stellantis, Eutelsat, Compagnie des Alpes, Generali, Expedia, Hargreaves Lansdown...	24-08-09
Les investisseurs retrouvent leur sang-froid	24-08-09
Borsa di Italia: Gli investitori si calmano	24-08-09
Bolsa de Madrid: Los inversores recuperan la calma	24-08-09

1 day	+5.24%
1 week	+9.87%
Current month	+11.17%
1 month	+13.44%
3 months	+22.99%
6 months	+20.40%
Current year	+21.25%

1 week	34.64	39.49
1 month	32.42	39.49
Current year	27.34	40
1 year	27.34	60.87
3 years	27.34	77.32
5 years	23.41	77.32
10 years	23.41	77.32

Manager	Title	Age	Since
Ying Huang CEO	Chief Executive Officer	52	2020-09-20
Jessie Yeung DFI	Director of Finance/CFO	40	2025-01-01
Mythili Koneru CTO	Chief Tech/Sci/R&D Officer	47	2023-04-10

Director	Title	Age	Since
Ye Wang CHM	Chairman	56	2020-11-05
Ying Huang BRD	Director/Board Member	52	2021-12-29
Corazon Sanders BRD	Director/Board Member	68	2020-04-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LEGEND BIOTECH CORPORATION	+5.24%	+9.87%	-15.53%	-29.61%	7.27B
ARGENX SE	+1.94%	+2.95%	+10.13%	+31.67%	33.32B
WUXI APPTEC CO., LTD.	-0.99%	-0.71%	+87.06%	-36.75%	27.79B
BIONTECH SE	+0.11%	+3.25%	+38.84%	-34.30%	27.52B
SUMMIT THERAPEUTICS INC.	+7.61%	+9.37%	+215.56%	+2,325.49%	18.37B
INSMED INCORPORATED	+0.34%	-1.80%	+37.28%	+288.99%	18.32B
WUXI BIOLOGICS (CAYMAN) INC.	-0.77%	-0.39%	+141.09%	-66.65%	13.43B
GENMAB A/S	+2.02%	+8.40%	-20.65%	-43.91%	13.23B
AKESO, INC.	-1.37%	+2.07%	+189.96%	+364.81%	12.55B
EXELIXIS, INC.	+1.29%	-0.52%	+98.96%	+100.23%	12.02B
Average	+0.84%	+3.59%	+78.27%	+290.00%	18.38B
Weighted average by Cap.	+0.60%	+2.82%	+73.72%	+278.56%

	2025 *	2026 *
Net sales	1.02B 874M 814M 753M 1.4B 87.69B 1.57B 9.75B 3.71B 40.97B 3.84B 3.76B 150B	1.57B 1.34B 1.25B 1.15B 2.15B 134B 2.4B 14.95B 5.69B 62.82B 5.88B 5.76B 230B
Net income	-143M -122M -114M -105M -196M -12.26B -219M -1.36B -518M -5.73B -536M -525M -20.96B	177M 151M 141M 130M 242M 15.15B 271M 1.68B 641M 7.08B 663M 649M 25.9B
Net Debt	-524M -447M -417M -386M -718M -44.89B -802M -4.99B -1.9B -20.97B -1.96B -1.92B -76.73B	-745M -636M -593M -548M -1.02B -63.86B -1.14B -7.1B -2.7B -29.83B -2.79B -2.74B -109B